drugset / Trial / NCT03077659
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
Open-label, dose rising, Phase IIa trial of intratumorally-injected NanoPac® 6, 10, or 15 mg/mL in subjects with prostate cancer scheduled for prostatectomy.
Timeline
- Start
- 2017-09-06
- Primary completion
- 2018-10-04
- Completion
- 2018-10-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NanoPac® | Unknown | 6 mg/ml | Other |
| Subject | NanoPac® | Unknown | 10 mg/ml | Other |
| Subject | NanoPac® | Unknown | 15 mg/ml | Other |